Published in J Hepatol on February 26, 2013
Cholangiocarcinoma. Lancet (2014) 4.52
Non-invasive diagnosis of small nodules in cirrhosis. J Hepatol (2013) 1.07
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol (2016) 0.96
Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management. Gastroenterol Res Pract (2015) 0.87
Detailed analysis of temporal features on contrast enhanced ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis. PLoS One (2014) 0.84
Dynamic enhancement patterns of intrahepatic cholangiocarcinoma in cirrhosis on contrast-enhanced computed tomography: risk of misdiagnosis as hepatocellular carcinoma. Sci Rep (2016) 0.76
Histone deacetylase inhibitor screening identifies HC toxin as the most effective in intrahepatic cholangiocarcinoma cells. Oncol Rep (2016) 0.75
Hepatobiliary Quiz Answers - 18 (2016). J Clin Exp Hepatol (2016) 0.75
Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Oncotarget (2016) 0.75
Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma? Diagn Interv Radiol (2014) 0.75
Recurrent Cardiac Tamponade: An Unusual Presentation of Intrahepatic Cholangiocarcinoma. ACG Case Rep J (2016) 0.75
Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography. BMC Cancer (2016) 0.75
Reply to: "non-invasive diagnosis of small nodules in cirrhosis". J Hepatol (2013) 0.75
Contrast-enhanced multiple-phase imaging features of intrahepatic mass-forming cholangiocarcinoma and hepatocellular carcinoma with cirrhosis: A comparative study. Oncol Lett (2017) 0.75
Predicting IDH mutation status of intrahepatic cholangiocarcinomas based on contrast-enhanced CT features. Eur Radiol (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med (2002) 10.78
The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut (2009) 6.50
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res (2007) 5.40
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology (2011) 4.60
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology (2007) 3.73
Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut (2007) 3.58
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology (2011) 3.26
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology (2012) 3.12
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology (2004) 2.91
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. J Hepatol (2011) 2.78
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology (2005) 2.50
The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol (2009) 2.47
Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol (2012) 2.39
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology (2006) 2.38
Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology (2011) 2.36
The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology (2006) 2.35
Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology (2009) 2.33
Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol (2004) 2.30
Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res (2010) 2.30
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2010) 2.28
The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol (2006) 2.27
Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int (2009) 2.27
In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. J Pathol (2012) 2.27
Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int (2014) 2.23
Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. J Hepatol (2013) 2.19
Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. Hepatology (2013) 2.16
MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2009) 2.16
When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. Hepatology (2015) 2.15
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? Liver Int (2014) 2.09
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation. Hepatology (2010) 2.06
Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl (2005) 2.04
Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology (2007) 2.03
The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol (2008) 2.03
MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med (2008) 1.99
Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol (2008) 1.98
Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology (2006) 1.92
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis (2013) 1.85
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res (2009) 1.84
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology (2009) 1.79
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology (2003) 1.78
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology (2011) 1.71
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology (2011) 1.70
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl (2005) 1.68
Characterization of focal liver lesions with contrast-enhanced ultrasound. Ultrasound Med Biol (2010) 1.67
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut (2012) 1.62
Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas. J Vasc Interv Radiol (2002) 1.62
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology (2005) 1.57
Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver Int (2013) 1.57
Liver AL amyloidosis as a possible cause of high liver stiffness values. Eur J Gastroenterol Hepatol (2010) 1.56
An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology (2009) 1.54
Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology (2011) 1.50
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology (2012) 1.49
Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B. Eur J Gastroenterol Hepatol (2010) 1.47
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology (2011) 1.40
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol (2010) 1.38
Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl (2005) 1.30
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology (2012) 1.29
Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation (2004) 1.27
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology (2012) 1.26
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology (2012) 1.23
Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol (2010) 1.23
Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis. Eur Radiol (2011) 1.22
Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl (2011) 1.22
A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology (2009) 1.22
Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. Cancer Res (2004) 1.21
Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation (2011) 1.18
Acoustic Radiation Force Impulse elastography for fibrosis evaluation in patients with chronic hepatitis C: an international multicenter study. Eur J Radiol (2012) 1.18
Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int (2007) 1.15
Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J Hepatol (2009) 1.14